Pfizer, Medtronic, Insmed named AI healthcare stocks to watch

The article comes from Simply Wall St's screener coverage, framing AI healthcare as a theme where large technology firms keep raising capital for massive AI projects even as rising interest rates pressure many asset classes. That sustained spending, in the article's telling, creates room for tools that cut costs and improve outcomes across healthcare — the backdrop for the three names it profiles.

Each company connects AI to a different part of the healthcare chain. Pfizer is described as a global biopharmaceutical company using large-scale research, including biomolecular AI models, and the article quotes a view that broader AI rollout across R&D, manufacturing and commercial operations is already used for yield improvement and field force productivity, supporting margin stability and EPS over time. Medtronic pairs devices with AI-enabled surgical and monitoring platforms, and its cited breakthroughs span digital health, robotics (Hugo), sensors and ecosystems like spine AiBLE. Insmed pairs rare respiratory disease therapies with early AI-driven protein engineering.

The article does not resolve how these efforts pay off. It repeatedly points to funding and execution pressures shaping the potential return, and to Pfizer's assumption about future cash generation as a question mark. Whether that AI work accelerates value or stalls appears to hinge on those pressures, and for Insmed, on how the anticipated brensocatib launch unfolds.